Catheter Precision (VTAK) AI Stock Analysis

• Market Cap: $2.85M
• Dividend Yield: N/A
• Average Volume (3M): 279.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: -4.98%
• EPS Growth: 95.05%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 9,268,632
• 10 Day Avg. Volume: 383,626
• 30 Day Avg. Volume: 279,756
• PEG Ratio: -0.03
• Price to Book (P/B): 0.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.28
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 0.92
• Enterprise Value/Gross Profit: 4.14
• Enterprise Value/Ebitda: -0.04
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

VTAK's overall stock score reflects significant financial challenges, including declining revenues and negative cash flows. Technical indicators show neutral to slightly bearish signals, and valuation metrics are weak due to ongoing losses. These factors highlight the need for strategic improvements to achieve financial health and investor confidence.

Catheter Precision Business Overview & Revenue Model

Company Description

Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.

How the Company Makes Money

Catheter Precision generates revenue primarily through the sale of its catheter-based medical devices to hospitals, clinics, and healthcare providers. The company may also engage in strategic partnerships with larger medical device firms to expand its market reach and distribution capabilities. Additionally, revenue streams could include licensing agreements for its proprietary technology and intellectual property, as well as potential service agreements for training and support related to the use of its products. The company’s earnings are influenced by factors such as the adoption rate of its technologies in healthcare facilities, the development of new products, and its ability to navigate regulatory approvals in various markets.

Catheter Precision Financial Statement Overview

Summary

VTAK's financial performance is concerning, with significant challenges in achieving profitability and positive cash flows. The income statement reflects a decline in revenue and persistent operational losses. While the balance sheet shows some stability with a manageable debt-to-equity ratio, negative return on equity due to ongoing losses is a concern. The cash flow statement highlights the need for improved operational efficiency as cash outflows exceed inflows.

Income Statement

The income statement reveals a significant decline in revenue from 2019 to 2024, with a negative revenue growth rate. Gross profit margin is positive, but both EBIT and net income margins are negative, indicating persistent operational losses. This suggests challenges in achieving profitability despite efforts to control costs.

Balance Sheet

The balance sheet highlights a moderately leveraged position with a debt-to-equity ratio that is manageable. However, the return on equity is negative due to continuing net losses, which is a concern for investor returns. The equity ratio shows a reasonable proportion of equity financing, suggesting some financial stability.

Cash Flow

Cash flow analysis shows ongoing negative free cash flow, indicating cash outflows that exceed inflows from operations. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. The company needs to improve operational efficiency to enhance cash generation.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
420.00K	442.00K	14.00K	22.00K	4.41M
	Gross Profit
378.00K	412.00K	-147.00K	-1.54M	-1.08M
	EBIT
-11.24M	-78.12M	-26.96M	-29.27M	-36.06M
	EBITDA
-11.30M	-15.11M	-22.37M	-27.70M	-33.30M
	Net Income Common Stockholders
-16.64M	-70.57M	-26.86M	-25.07M	-36.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.87M	3.56M	15.86M	15.04M	23.91M
	Total Assets
27.77M	30.74M	16.84M	21.04M	33.44M
	Total Debt
1.79M	372.00K	124.17K	2.26M	4.88M
	Net Debt
-1.08M	-3.19M	-15.73M	-12.78M	-19.02M
	Total Liabilities
16.01M	9.54M	7.58M	7.37M	12.29M
	Stockholders Equity
11.76M	21.19M	9.26M	13.67M	21.15M
Cash Flow		Free Cash Flow
-9.34M	-20.70M	-22.59M	-27.89M	-28.37M
	Operating Cash Flow
-9.27M	-20.62M	-22.57M	-27.63M	-28.30M
	Investing Cash Flow
-67.00K	-61.00K	21.00K	3.80M	15.93M
	Financing Cash Flow
8.65M	8.39M	23.36M	14.96M	21.69M

Catheter Precision Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.33, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 49.68 is Neutral, neither overbought nor oversold. The STOCH value of 62.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTAK.

Catheter Precision Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VVOS	57 Neutral	$18.49M	―	-266.25%	―	8.91%	70.18%
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%
NUWE	49 Neutral	$4.33M	―	-440.77%	―	-1.21%	93.72%
SINT	42 Neutral	$8.32M	―	-174.07%	―	9.90%	94.56%
RSLS	37 Underperform	$2.82M	―	-222.46%	―	-7.74%	93.25%
VTAK	36 Underperform	$2.85M	―	-101.02%	―	-4.98%	95.05%
HSCS	35 Underperform	$3.60M	―	-163.47%	―	-100.00%	78.91%

Catheter Precision Corporate Events

Catheter Precision Enters Securities Purchase Agreement

On May 12, 2025, Catheter Precision, Inc. entered into a Securities Purchase Agreement with three investors, selling 1.5 million shares of its Series B Convertible Preferred Stock and issuing an additional 1.5 million shares as consideration for existing senior secured Convertible Promissory Notes of QHSLab, Inc. The company has reserved up to 8,574,000 shares of common stock for conversion and issued Series L warrants for purchasing up to 4,285,716 shares of common stock. The conversion and exercise of these securities are subject to stockholder approval, which the company plans to seek at its Annual Meeting on July 25, 2025. The Series B Convertible Preferred Stock has a fixed conversion price of $0.35 per share, while the Series L warrants have a 5 ½ year term and are exercisable at $0.50 per share. The securities offering was conducted under an exemption from registration requirements, and the company intends to register the shares for resale by May 27, 2025.

Spark’s Take on VTAK Stock

According to Spark, TipRanks’ AI Analyst, VTAK is a Underperform.

VTAK’s overall stock score reflects significant challenges in financial performance, particularly in achieving profitability and generating positive cash flows. Technical analysis indicates a bearish trend, with the stock trading below key moving averages. Valuation remains unattractive due to ongoing losses and a negative P/E ratio. While the corporate event of an executive stock option plan is positive, it does not materially improve the current financial and technical outlook.

To see Spark’s full report on VTAK stock, click here.

Catheter Precision Finalizes Strategic Cardiac Acquisition

In February 2025, Catheter Precision, Inc. formed a subsidiary, Cardionomix, Inc., to acquire assets from Cardionomic, Inc., which had ceased operations. On April 18, 2025, Cardionomix entered into an agreement to purchase assets related to a late-stage treatment for acute decompensated heart failure, including patents and trademarks for the Cardiac Pulmonary Nerve Simulation System. The acquisition was finalized on May 5, 2025, with Catheter Precision issuing 1,000,000 restricted shares and Cardionomix providing a $1.5 million promissory note. This strategic acquisition aims to enhance Catheter Precision’s portfolio in cardiac care, although it involves financial obligations and potential equity dilution for stakeholders.

Spark’s Take on VTAK Stock

According to Spark, TipRanks’ AI Analyst, VTAK is a Underperform.

VTAK’s overall stock score reflects significant challenges in financial performance, particularly in achieving profitability and generating positive cash flows. Technical analysis indicates a bearish trend, with the stock trading below key moving averages. Valuation remains unattractive due to ongoing losses and a negative P/E ratio. While the corporate event of an executive stock option plan is positive, it does not materially improve the current financial and technical outlook.

To see Spark’s full report on VTAK stock, click here.